If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> EUROPEAN MEDICAL JOURNAL<br /> ISSN 2397-6764 Vol 3.2 • June 2018 • europeanmedical-journal.com<br /> Contents<br /> EDITORIAL BOARD 4<br /> 01 FEATURE<br /> Plotting a Better Pathway for Parkinson’s Disease: A New Composite 12<br /> Scale from My PD Journey<br /> Lizzie Graham et al.<br /> 02 SYMPOSIUM REVIEWS<br /> Delivering Precision Medicine and Patient-Centred Care Through 17<br /> a Multidisciplinary Approach<br /> Treating Psoriasis: What Is New About Fumaric Acid Esters? 25<br /> Anti-Tumour Necrosis Factor in Inflammatory Bowel Disease: 34<br /> Inventory and Outlook<br /> 03 ARTICLES<br /> Editor’s Pick: <a title="EMJ 3.2 2018 page 1" href="http://viewer.zmags.com/publication/d94cc7ab?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a> <a title="EMJ 3.2 2018 page 2" href="http://viewer.zmags.com/publication/d94cc7ab?page=2"> Contents EDITORIAL BOARD </a> <a title="EMJ 3.2 2018 page 3" href="http://viewer.zmags.com/publication/d94cc7ab?page=3"> “I am honoured and delighted to welcome yo</a> <a title="EMJ 3.2 2018 page 4" href="http://viewer.zmags.com/publication/d94cc7ab?page=4"> Editorial Board Editor-in-Chief Prof Markus Peck-</a> <a title="EMJ 3.2 2018 page 5" href="http://viewer.zmags.com/publication/d94cc7ab?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ 3.2 2018 page 6" href="http://viewer.zmags.com/publication/d94cc7ab?page=6"> EMJ 3.2 Chief Executive Officer Spencer Gore Seni</a> <a title="EMJ 3.2 2018 page 7" href="http://viewer.zmags.com/publication/d94cc7ab?page=7"> Welcome I am honoured and delighted to welcome yo</a> <a title="EMJ 3.2 2018 page 8" href="http://viewer.zmags.com/publication/d94cc7ab?page=8"> In indolent NHL… As our knowledge evolves, so sho</a> <a title="EMJ 3.2 2018 page 9" href="http://viewer.zmags.com/publication/d94cc7ab?page=9"> Foreword Dear colleagues and readers of the Europ</a> <a title="EMJ 3.2 2018 page 10" href="http://viewer.zmags.com/publication/d94cc7ab?page=10"> Available now. HEPATOLOGY ISSN 2053-4221 </a> <a title="EMJ 3.2 2018 page 11" href="http://viewer.zmags.com/publication/d94cc7ab?page=11"> Featured inside: Congress Reviews + Review of </a> <a title="EMJ 3.2 2018 page 12" href="http://viewer.zmags.com/publication/d94cc7ab?page=12"> Plotting a Better Pathway for Parkinson’s Disease</a> <a title="EMJ 3.2 2018 page 13" href="http://viewer.zmags.com/publication/d94cc7ab?page=13"> over a year; far longer than the maximum of 6 we</a> <a title="EMJ 3.2 2018 page 14" href="http://viewer.zmags.com/publication/d94cc7ab?page=14"> decision-makers in Brussels to advocate My PD Jou</a> <a title="EMJ 3.2 2018 page 15" href="http://viewer.zmags.com/publication/d94cc7ab?page=15"> study of the composite scale. This multicentre st</a> <a title="EMJ 3.2 2018 page 16" href="http://viewer.zmags.com/publication/d94cc7ab?page=16"> Raise Your EXPECTATIONS This advert is int</a> <a title="EMJ 3.2 2018 page 17" href="http://viewer.zmags.com/publication/d94cc7ab?page=17"> Delivering Precision Medicine and Patient-Centred</a> <a title="EMJ 3.2 2018 page 18" href="http://viewer.zmags.com/publication/d94cc7ab?page=18"> Personalised medicine will have a profound impact</a> <a title="EMJ 3.2 2018 page 19" href="http://viewer.zmags.com/publication/d94cc7ab?page=19"> Currently, the typically applied definition o</a> <a title="EMJ 3.2 2018 page 20" href="http://viewer.zmags.com/publication/d94cc7ab?page=20"> well as other IBD indications. Furthermore, </a> <a title="EMJ 3.2 2018 page 21" href="http://viewer.zmags.com/publication/d94cc7ab?page=21"> PsA and their effect on treatment, and provided d</a> <a title="EMJ 3.2 2018 page 22" href="http://viewer.zmags.com/publication/d94cc7ab?page=22"> New Multidisciplinary Approaches: What Does the F</a> <a title="EMJ 3.2 2018 page 23" href="http://viewer.zmags.com/publication/d94cc7ab?page=23"> Panel Discussion Precision Medicine: Current </a> <a title="EMJ 3.2 2018 page 24" href="http://viewer.zmags.com/publication/d94cc7ab?page=24"> colitis: A critical appraisal of clinical paramet</a> <a title="EMJ 3.2 2018 page 25" href="http://viewer.zmags.com/publication/d94cc7ab?page=25"> Treating Psoriasis: What Is</a> <a title="EMJ 3.2 2018 page 26" href="http://viewer.zmags.com/publication/d94cc7ab?page=26"> Augustin reviewed advances in the systemic treatm</a> <a title="EMJ 3.2 2018 page 27" href="http://viewer.zmags.com/publication/d94cc7ab?page=27"> > Arsenic > Ammoniated mercury > Crude coal tar ></a> <a title="EMJ 3.2 2018 page 28" href="http://viewer.zmags.com/publication/d94cc7ab?page=28"> from psoriasis for the selection of biologi</a> <a title="EMJ 3.2 2018 page 29" href="http://viewer.zmags.com/publication/d94cc7ab?page=29"> strategies indicated that while there is no</a> <a title="EMJ 3.2 2018 page 30" href="http://viewer.zmags.com/publication/d94cc7ab?page=30"> A Marked improved and cleared Slightly improved </a> <a title="EMJ 3.2 2018 page 31" href="http://viewer.zmags.com/publication/d94cc7ab?page=31"> FAE are able to mount an effective immune respons</a> <a title="EMJ 3.2 2018 page 32" href="http://viewer.zmags.com/publication/d94cc7ab?page=32"> Global Report on Psoriasis. 2016. Available at: h</a> <a title="EMJ 3.2 2018 page 33" href="http://viewer.zmags.com/publication/d94cc7ab?page=33"> 2017;264(6):1155-64. 45. Balak DMW et al. Progre</a> <a title="EMJ 3.2 2018 page 34" href="http://viewer.zmags.com/publication/d94cc7ab?page=34"> Anti-Tumour Necrosis Factor in Inflammatory </a> <a title="EMJ 3.2 2018 page 35" href="http://viewer.zmags.com/publication/d94cc7ab?page=35"> Citation: EMJ. 2018;3[2]:34-</a> <a title="EMJ 3.2 2018 page 36" href="http://viewer.zmags.com/publication/d94cc7ab?page=36"> D’Haens shared their personal experience,</a> <a title="EMJ 3.2 2018 page 37" href="http://viewer.zmags.com/publication/d94cc7ab?page=37"> Key Aspects of Patient Communication When discus</a> <a title="EMJ 3.2 2018 page 38" href="http://viewer.zmags.com/publication/d94cc7ab?page=38"> Reinvesting Savings into the Clinic If the n</a> <a title="EMJ 3.2 2018 page 39" href="http://viewer.zmags.com/publication/d94cc7ab?page=39"> armamentarium, clinics need to also sta</a> <a title="EMJ 3.2 2018 page 40" href="http://viewer.zmags.com/publication/d94cc7ab?page=40"> T1 delayed enhancement instensity Duration of ob</a> <a title="EMJ 3.2 2018 page 41" href="http://viewer.zmags.com/publication/d94cc7ab?page=41"> The case studies discussed during this meeting hi</a> <a title="EMJ 3.2 2018 page 42" href="http://viewer.zmags.com/publication/d94cc7ab?page=42"> Pyruvate Kinase and Gastric Cancer: A Potential </a> <a title="EMJ 3.2 2018 page 43" href="http://viewer.zmags.com/publication/d94cc7ab?page=43"> the blood or stools could be a good marker for ga</a> <a title="EMJ 3.2 2018 page 44" href="http://viewer.zmags.com/publication/d94cc7ab?page=44"> Table 1: The main results of selected studies. St</a> <a title="EMJ 3.2 2018 page 45" href="http://viewer.zmags.com/publication/d94cc7ab?page=45"> Table 1 continued. Study Sample Conclusio</a> <a title="EMJ 3.2 2018 page 46" href="http://viewer.zmags.com/publication/d94cc7ab?page=46"> DISCUSSION MicroRNA (miRNA) are small non-coding </a> <a title="EMJ 3.2 2018 page 47" href="http://viewer.zmags.com/publication/d94cc7ab?page=47"> depth of tumour invasion, and tumour size. </a> <a title="EMJ 3.2 2018 page 48" href="http://viewer.zmags.com/publication/d94cc7ab?page=48"> lower than that in the diagnosis of colorectal ca</a> <a title="EMJ 3.2 2018 page 49" href="http://viewer.zmags.com/publication/d94cc7ab?page=49"> EGF/EGFR signaling via E-cadherin- dependent mann</a> <a title="EMJ 3.2 2018 page 50" href="http://viewer.zmags.com/publication/d94cc7ab?page=50"> Slowing Progression of Airway Diseases by Smoking</a> <a title="EMJ 3.2 2018 page 51" href="http://viewer.zmags.com/publication/d94cc7ab?page=51"> INTRODUCTION The health, economic, and social</a> <a title="EMJ 3.2 2018 page 52" href="http://viewer.zmags.com/publication/d94cc7ab?page=52"> and quality of life.19,20 For COPD, smoking cessa</a> <a title="EMJ 3.2 2018 page 53" href="http://viewer.zmags.com/publication/d94cc7ab?page=53"> asthma exacerbations following influenza </a> <a title="EMJ 3.2 2018 page 54" href="http://viewer.zmags.com/publication/d94cc7ab?page=54"> In addition to the current vaccination schedule (</a> <a title="EMJ 3.2 2018 page 55" href="http://viewer.zmags.com/publication/d94cc7ab?page=55"> the efficacy of this treatment. In</a> <a title="EMJ 3.2 2018 page 56" href="http://viewer.zmags.com/publication/d94cc7ab?page=56"> exacerbations are actually due to a pathological </a> <a title="EMJ 3.2 2018 page 57" href="http://viewer.zmags.com/publication/d94cc7ab?page=57"> Table 2 continued. Intervention Patients with</a> <a title="EMJ 3.2 2018 page 58" href="http://viewer.zmags.com/publication/d94cc7ab?page=58"> factors and the global burden of 23. </a> <a title="EMJ 3.2 2018 page 59" href="http://viewer.zmags.com/publication/d94cc7ab?page=59"> JAMA Intern Med. 2016;176(11):1630-7. 50. Vollen</a> <a title="EMJ 3.2 2018 page 60" href="http://viewer.zmags.com/publication/d94cc7ab?page=60"> Initiatives to Improve Safety of Oral Anticancer </a> <a title="EMJ 3.2 2018 page 61" href="http://viewer.zmags.com/publication/d94cc7ab?page=61"> ANTICANCER AGENTS GROWTH IN ORAL In recent y</a> <a title="EMJ 3.2 2018 page 62" href="http://viewer.zmags.com/publication/d94cc7ab?page=62"> Number of new licensed cancer drugs 2001-</a> <a title="EMJ 3.2 2018 page 63" href="http://viewer.zmags.com/publication/d94cc7ab?page=63"> COMMUNITY PHARMACISTS INCREASED ROLE FOR The he</a> <a title="EMJ 3.2 2018 page 64" href="http://viewer.zmags.com/publication/d94cc7ab?page=64"> Standards for OAA have also been produced by a </a> <a title="EMJ 3.2 2018 page 65" href="http://viewer.zmags.com/publication/d94cc7ab?page=65"> tamoxifen (half-life: 7–14 days)37 than miss</a> <a title="EMJ 3.2 2018 page 66" href="http://viewer.zmags.com/publication/d94cc7ab?page=66"> Figure 3: Screenshot of the online database devel</a> <a title="EMJ 3.2 2018 page 67" href="http://viewer.zmags.com/publication/d94cc7ab?page=67"> when they see their oncologists. The initiative a</a> <a title="EMJ 3.2 2018 page 68" href="http://viewer.zmags.com/publication/d94cc7ab?page=68"> 21. Weingart SN et al. Oral chemotherapy </a> <a title="EMJ 3.2 2018 page 69" href="http://viewer.zmags.com/publication/d94cc7ab?page=69"> </a> <a title="EMJ 3.2 2018 page 70" href="http://viewer.zmags.com/publication/d94cc7ab?page=70"> Overactive Bladder in Children Authors: </a> <a title="EMJ 3.2 2018 page 71" href="http://viewer.zmags.com/publication/d94cc7ab?page=71"> LUT symptoms Psychological dysfunction C</a> <a title="EMJ 3.2 2018 page 72" href="http://viewer.zmags.com/publication/d94cc7ab?page=72"> lack of attention, voiding postponement may be t</a> <a title="EMJ 3.2 2018 page 73" href="http://viewer.zmags.com/publication/d94cc7ab?page=73"> A B Vur 100 mL/ Div V V ur=7 Vur 100 m</a> <a title="EMJ 3.2 2018 page 74" href="http://viewer.zmags.com/publication/d94cc7ab?page=74"> tolterodine) is also an option; a previous study </a> <a title="EMJ 3.2 2018 page 75" href="http://viewer.zmags.com/publication/d94cc7ab?page=75"> studies have already been completed. In one study</a> <a title="EMJ 3.2 2018 page 76" href="http://viewer.zmags.com/publication/d94cc7ab?page=76"> Standardization Committee of the International Ch</a> <a title="EMJ 3.2 2018 page 77" href="http://viewer.zmags.com/publication/d94cc7ab?page=77"> 48. Yang S et al. Diagnosis and manageme</a> <a title="EMJ 3.2 2018 page 78" href="http://viewer.zmags.com/publication/d94cc7ab?page=78"> Multiple Myeloma: Personalised Medicine Based on</a> <a title="EMJ 3.2 2018 page 79" href="http://viewer.zmags.com/publication/d94cc7ab?page=79"> required to understand the pathogenesis and targe</a> <a title="EMJ 3.2 2018 page 80" href="http://viewer.zmags.com/publication/d94cc7ab?page=80"> genes are hypermethylated early in MM, and increa</a> <a title="EMJ 3.2 2018 page 81" href="http://viewer.zmags.com/publication/d94cc7ab?page=81"> Table 1: Potential multiple myeloma treatments ba</a> <a title="EMJ 3.2 2018 page 82" href="http://viewer.zmags.com/publication/d94cc7ab?page=82"> Table 1 continued. Genes Cytokines/proteins</a> <a title="EMJ 3.2 2018 page 83" href="http://viewer.zmags.com/publication/d94cc7ab?page=83"> and ANXA2P2, are also related to myeloma cell adh</a> <a title="EMJ 3.2 2018 page 84" href="http://viewer.zmags.com/publication/d94cc7ab?page=84"> three groups: high-risk, including del(17</a> <a title="EMJ 3.2 2018 page 85" href="http://viewer.zmags.com/publication/d94cc7ab?page=85"> investigating the activity of miRNA mimics o</a> <a title="EMJ 3.2 2018 page 86" href="http://viewer.zmags.com/publication/d94cc7ab?page=86"> with proteasome inhibitors.73-76 This combined th</a> <a title="EMJ 3.2 2018 page 87" href="http://viewer.zmags.com/publication/d94cc7ab?page=87"> References 1. Rossi M et al. MicroRNA and </a> <a title="EMJ 3.2 2018 page 88" href="http://viewer.zmags.com/publication/d94cc7ab?page=88"> 2015;263(1):160-72. 43. Song W et al. Generation</a> <a title="EMJ 3.2 2018 page 89" href="http://viewer.zmags.com/publication/d94cc7ab?page=89"> study of pembrolizumab (MK-3475) in combination w</a> <a title="EMJ 3.2 2018 page 90" href="http://viewer.zmags.com/publication/d94cc7ab?page=90"> Modern Methods for Studying Portal Hypertension</a> <a title="EMJ 3.2 2018 page 91" href="http://viewer.zmags.com/publication/d94cc7ab?page=91"> INTRODUCTION Portal hypertension (PH) is asso</a> <a title="EMJ 3.2 2018 page 92" href="http://viewer.zmags.com/publication/d94cc7ab?page=92"> Table 1: Advantages and disadvantages of intrahep</a> <a title="EMJ 3.2 2018 page 93" href="http://viewer.zmags.com/publication/d94cc7ab?page=93"> imaging, the slices are obtained by rotating the </a> <a title="EMJ 3.2 2018 page 94" href="http://viewer.zmags.com/publication/d94cc7ab?page=94"> week for 18 weeks to keep body weight within a 25</a> <a title="EMJ 3.2 2018 page 95" href="http://viewer.zmags.com/publication/d94cc7ab?page=95"> animals, in contrast to permeability in animals w</a> <a title="EMJ 3.2 2018 page 96" href="http://viewer.zmags.com/publication/d94cc7ab?page=96"> > Video images should be stored in full size </a> <a title="EMJ 3.2 2018 page 97" href="http://viewer.zmags.com/publication/d94cc7ab?page=97"> images of immunohistochemically stained </a> <a title="EMJ 3.2 2018 page 98" href="http://viewer.zmags.com/publication/d94cc7ab?page=98"> β-adrenoblockers are not recommended for use </a> <a title="EMJ 3.2 2018 page 99" href="http://viewer.zmags.com/publication/d94cc7ab?page=99"> J Gastroenterol. 2005;11(6):846-9. 32. Yamaki K </a> <a title="EMJ 3.2 2018 page 100" href="http://viewer.zmags.com/publication/d94cc7ab?page=100"> Management of Non-Small Cell Lung Cancer: </a> <a title="EMJ 3.2 2018 page 101" href="http://viewer.zmags.com/publication/d94cc7ab?page=101"> patients with high PD-L1 expression (≥50% of</a> <a title="EMJ 3.2 2018 page 102" href="http://viewer.zmags.com/publication/d94cc7ab?page=102"> cut-off limits would lead to misclassification of </a> <a title="EMJ 3.2 2018 page 103" href="http://viewer.zmags.com/publication/d94cc7ab?page=103"> inhibition.7 Finally, the hypothesis of a r</a> <a title="EMJ 3.2 2018 page 104" href="http://viewer.zmags.com/publication/d94cc7ab?page=104"> APPROACHES AND FUTURE DIRECTIONS CURRENT IMMUNOT</a> <a title="EMJ 3.2 2018 page 105" href="http://viewer.zmags.com/publication/d94cc7ab?page=105"> leading to an objective response in 55% of all pa</a> <a title="EMJ 3.2 2018 page 106" href="http://viewer.zmags.com/publication/d94cc7ab?page=106"> give clarity regarding how different combination </a> <a title="EMJ 3.2 2018 page 107" href="http://viewer.zmags.com/publication/d94cc7ab?page=107"> 34. Hellmann MD et al. Nivolumab plus </a> <a title="EMJ 3.2 2018 page 108" href="http://viewer.zmags.com/publication/d94cc7ab?page=108"> Practical Diagnosis and Staging of Nonalcoholic </a> <a title="EMJ 3.2 2018 page 109" href="http://viewer.zmags.com/publication/d94cc7ab?page=109"> central obesity and metabolic syndrome; almost al</a> <a title="EMJ 3.2 2018 page 110" href="http://viewer.zmags.com/publication/d94cc7ab?page=110"> risk of more advanced NAFLD. A recent study scree</a> <a title="EMJ 3.2 2018 page 111" href="http://viewer.zmags.com/publication/d94cc7ab?page=111"> results. MRI-PDFF, the newest technique, has the </a> <a title="EMJ 3.2 2018 page 112" href="http://viewer.zmags.com/publication/d94cc7ab?page=112"> Table 1: An overview of the simple noninvasive fib</a> <a title="EMJ 3.2 2018 page 113" href="http://viewer.zmags.com/publication/d94cc7ab?page=113"> score performed slightly better than the NFS in m</a> <a title="EMJ 3.2 2018 page 114" href="http://viewer.zmags.com/publication/d94cc7ab?page=114"> The Enhanced Liver Fibrosis (ELFTM) Test This </a> <a title="EMJ 3.2 2018 page 115" href="http://viewer.zmags.com/publication/d94cc7ab?page=115"> Individuals at risk of NAFLD Central </a> <a title="EMJ 3.2 2018 page 116" href="http://viewer.zmags.com/publication/d94cc7ab?page=116"> levels may not help with diagnosis in individual </a> <a title="EMJ 3.2 2018 page 117" href="http://viewer.zmags.com/publication/d94cc7ab?page=117"> of healthy ranges for serum alanine aminotransfer</a> <a title="EMJ 3.2 2018 page 118" href="http://viewer.zmags.com/publication/d94cc7ab?page=118"> review & meta-analysis. PLoS One. 67. 20</a> <a title="EMJ 3.2 2018 page 119" href="http://viewer.zmags.com/publication/d94cc7ab?page=119"> New Insights into the Role of Phosphoinositid</a> <a title="EMJ 3.2 2018 page 120" href="http://viewer.zmags.com/publication/d94cc7ab?page=120"> KITL Pre-granulosa cell Oocyte PTEN PDK1 </a> <a title="EMJ 3.2 2018 page 121" href="http://viewer.zmags.com/publication/d94cc7ab?page=121"> it is then phosphorylated and activated by </a> <a title="EMJ 3.2 2018 page 122" href="http://viewer.zmags.com/publication/d94cc7ab?page=122"> the loss of PTEN. Hence, we generated an o</a> <a title="EMJ 3.2 2018 page 123" href="http://viewer.zmags.com/publication/d94cc7ab?page=123"> TAp63α-regulated oocyte apoptosis, and their foll</a> <a title="EMJ 3.2 2018 page 124" href="http://viewer.zmags.com/publication/d94cc7ab?page=124"> CONSEQUENCES OF EXCESS PHOSPHATIDYLINOSITOL (3,4,</a> <a title="EMJ 3.2 2018 page 125" href="http://viewer.zmags.com/publication/d94cc7ab?page=125"> References 1. Findlay JK et al. What is the </a> <a title="EMJ 3.2 2018 page 126" href="http://viewer.zmags.com/publication/d94cc7ab?page=126"> The Adverse Impact of Sarcopenia and Visceral</a> <a title="EMJ 3.2 2018 page 127" href="http://viewer.zmags.com/publication/d94cc7ab?page=127"> are considered for nonsurgical treatment </a> <a title="EMJ 3.2 2018 page 128" href="http://viewer.zmags.com/publication/d94cc7ab?page=128"> not measured following adjustment for age, s</a> <a title="EMJ 3.2 2018 page 129" href="http://viewer.zmags.com/publication/d94cc7ab?page=129"> Table 2: Summary of studies evaluating the effect</a> <a title="EMJ 3.2 2018 page 130" href="http://viewer.zmags.com/publication/d94cc7ab?page=130"> to-subcutaneous adiposity ratio and low mean musc</a> <a title="EMJ 3.2 2018 page 131" href="http://viewer.zmags.com/publication/d94cc7ab?page=131"> Table 3 continued. Study Study design Par</a> <a title="EMJ 3.2 2018 page 132" href="http://viewer.zmags.com/publication/d94cc7ab?page=132"> BCAA supplementation in 40 patients 1 month prior</a> <a title="EMJ 3.2 2018 page 133" href="http://viewer.zmags.com/publication/d94cc7ab?page=133"> considered for hepatectomy should receive int</a> <a title="EMJ 3.2 2018 page 134" href="http://viewer.zmags.com/publication/d94cc7ab?page=134"> article. Medicine (Baltimore). </a> <a title="EMJ 3.2 2018 page 135" href="http://viewer.zmags.com/publication/d94cc7ab?page=135"> Interact with us on social media. </a> <a title="EMJ 3.2 2018 page 136" href="http://viewer.zmags.com/publication/d94cc7ab?page=136"> What's New Striking a Balance Between Vitamin D </a> <a title="EMJ 3.2 2018 page 137" href="http://viewer.zmags.com/publication/d94cc7ab?page=137"> JAK Inhibitors and Alopecia RESEARCHERS from Colu</a> <a title="EMJ 3.2 2018 page 138" href="http://viewer.zmags.com/publication/d94cc7ab?page=138"> What's New Genetic Variation Determines Survival</a> <a title="EMJ 3.2 2018 page 139" href="http://viewer.zmags.com/publication/d94cc7ab?page=139"> Idiopathic Pulmonary Fibrosis: Targeting Preventi</a> <a title="EMJ 3.2 2018 page 140" href="http://viewer.zmags.com/publication/d94cc7ab?page=140"> Never miss an update again. J</a>